Lymphatic Circulation—Physiology, Venous Coupling, and Clinical Implications

The lymphatic system functions as a parallel return circuit for fluid, macromolecules, and immune cells. Under physiologic conditions, the venous microcirculation reabsorbs most capillary filtrate, while lymphatics remove the protein-rich fraction that cannot be reclaimed by veins, thereby preventing interstitial oncotic trapping and edema. Approximately 85–90% of interstitial fluid returns venously and the remainder (~10–15%) via lymphatics; although numerically smaller, this lymphatic fraction is essential for clearing proteins, lipids, and immune cargo and for maintaining low interstitial oncotic pressure.

Drainage pathway and the low-pressure destination

Blind-ended initial lymphatics converge into valved collecting vessels (lymphangions) and then into central conduits—the thoracic duct and right lymphatic duct—that empty at the internal jugular–subclavian venous junctions. Because the terminal lymph–venous pressure gradient is small, lymph return is exquisitely sensitive to central venous pressure (CVP). Even modest, sustained increases in CVP can narrow or reverse the gradient and precipitate upstream lymphatic congestion and leak.

What propels lymph

Lymph propulsion reflects the interaction of intrinsic and extrinsic pumps. Intrinsically, segmental smooth muscle within collecting lymphatics produces rhythmic, valved peristalsis; nitric-oxide–shear coupling coordinates contractions. Extrinsically, skeletal-muscle compression, transmitted arterial pulsations, and the respiratory pump (inspiratory falls in intrathoracic pressure) augment forward flow. Conceptually, lymphangions have preload (filling) and afterload (outflow pressure at the lymph–venous junction): lymph flow falters when preload is inadequate or when afterload (CVP) is high.

Coupling to the venous system—and why CVP matters

Because ducts drain directly into thoracic veins, the lymphatic circuit is effectively in series with the venous system. Chronic venous hypertension—right-sided heart failure, superior vena cava (SVC) or innominate vein obstruction, or single-ventricle surgical circulations—impairs lymph entry into the veins and elevates upstream lymphatic pressures, driving lymph into low-pressure compartments (pleura, airways, gut). In Fontan patients specifically, plastic bronchitis occurs in ~4% (typically within 2–3 years of completion) and protein-losing enteropathy (PLE) in ~4–13% (usually 5–10 years later), both mechanistically linked to lymphatic dysfunction under elevated venous pressures and altered capillary–interstitial forces [1, 2]. PubMed+1

Fontan physiology as a prototypical lymphatic failure

The absence of a subpulmonary ventricle imposes a chronically elevated CVP and reduced diastolic suction. Human mechanistic data show impaired lymphatic pumping capacity in Fontan patients—~17% lower pumping pressure and ~62% higher contraction frequency versus controls—and morphologic duct abnormalities, consistent with a stressed, high-afterload lymphatic network [3]. These hemodynamic and structural derangements underlie chylothorax, plastic bronchitis, and PLE—now recognized as lymphatic diseases rather than isolated local problems [1–3, 5].

Imaging the lymphatic system

Modern imaging has transformed diagnosis and procedural planning:

• Non-contrast T2-weighted MR lymphangiography screens central lymphatic anatomy, grades thoracic abnormalities, and tracks progression over the Glenn–Fontan course; progression to high-grade patterns correlates with longer drainage/hospitalization and higher risks of chylothorax and PLE [4].
• Dynamic contrast-enhanced MR lymphangiography (DCMRL)—intranodal (IN-DCMRL), intrahepatic (IH-DCMRL), and (in select centers) intramesenteric (IM-DCMRL)—maps flow sources and leak pathways to airways (plastic bronchitis), pleura, and duodenum (PLE), enabling targeted interventions [5, 6, 8].

Management—principles and pathways

1. Hemodynamic optimization (always first): Identify and correct reversible lesions (e.g., SVC/innominate/PA obstruction, AV valve regurgitation); keep CVP as low as safely achievable; recruit pulmonary vascular bed; set ventilatory support to preserve the inspiratory pump and avoid excessive mean airway pressure [1, 2, 6].
2. Conservative measures: Nutritional strategies (MCT diet or temporary TPN for chyle), diuretics, and selective pharmacotherapy (e.g., octreotide in high-output chylous states) while definitive plans are arranged [1, 6].
3. Targeted lymphatic interventions (imaging-guided):
• Selective lymphatic duct embolization (SLDE) or thoracic duct embolization (TDE) when abnormal pulmonary/mediastinal or duodenal lymphatic perfusion is demonstrated, with a bias toward preserving central duct patency when feasible [5–6].
• Thoracic duct decompression (TDD)—percutaneous or surgical—for multi-compartment lymphatic failure or when outflow afterload at the lymph–venous junction is the dominant problem; emerging series show promising symptom control in failing Fontan physiology [7].
• IH-DCMRL–guided embolization of hepatoduodenal/periduodenal channels for PLE, given the frequent duodenal involvement demonstrated by hepatic lymphatic injections [8].
4. Escalation: If refractory after hemodynamic and lymphatic interventions, consider Fontan fenestration (creation/enlargement), Fontan takedown, mechanical support, or transplantation—framed by the patient’s overall Fontan pathway anatomy and end-organ reserve [1, 6].

Practical teaching points

• CVP is lymphatic afterload: lowering CVP reliably improves lymph flow; raising it worsens lymphatic congestion [1, 2].
• Imaging drives therapy: Use T2-MR for screening/phenotyping; add targeted DCMRL (IN/IH/IM) to answer “where is the flow coming from/going to?” before any embolization or decompression [4–6].
• Fontan lymphatic failure is a circuit problem: treat venous hemodynamics and lymphatic routes together; avoid duct-occlusive procedures when central flow is normal and the pathology is hepatopulmonary or mesenteric [6].

References

[1] Mackie AS, Veldtman GR, Thorup L, Hjortdal VE, Dori Y. Plastic Bronchitis and Protein-Losing Enteropathy in the Fontan Patient: Evolving Understanding and Emerging Therapies. Can J Cardiol. 2022;38(7):988-1001. PubMed

[2] RochéRodríguez M, DiNardo JA. The Lymphatic System in the Fontan Patient—Pathophysiology, Imaging, and Interventions: What the Anesthesiologist Should Know. J Cardiothorac Vasc Anesth. 2022;36(8 Pt A):2669-2678. PubMed

[3] Mohanakumar S, Telinius N, Kelly B, Lauridsen H, Boedtkjer D, Pedersen M, de Leval M, Hjortdal V. Morphology and Function of the Lymphatic Vasculature in Patients With a Fontan Circulation. Circ Cardiovasc Imaging. 2019;12(4):e008074. PubMed

[4] Kelly B, Mohanakumar S, Ford B, Smith CL, Pinto E, Biko DM, Hjortdal VE, Dori Y. Sequential MRI Evaluation of Lymphatic Abnormalities Over the Course of Fontan Completion. Radiol Cardiothorac Imaging. 2024;6(3):e230315. PubMed

[5] Bauer C, Scala M, Rome JJ, Tulzer G, Dori Y. Lymphatic Imaging and Intervention in Congenital Heart Disease. J Soc Cardiovasc Angiogr Interv. 2023;3(1):101174 (eCollection 2024). PubMed

[6] Dori Y, Smith CL. Lymphatic Disorders in Patients With Single Ventricle Heart Disease. Front Cardiovasc Med. 2022;9:9226478. PMC

[7] Smith CL, Biko DM, Dori Y, et al. Transcatheter Thoracic Duct Decompression for Multicompartment Lymphatic Failure in Patients With Fontan Physiology. Circ Cardiovasc Interv. 2022;15(6):e011733. PubMed

[8] Lemley BA, Biko DM, Dori Y, et al. Intrahepatic Dynamic Contrast-Enhanced MR Lymphangiography in Pediatric Patients: Technique and Initial Experience. Radiology. 2021;301(3):640-648. PMC